Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Arcturus Therapeutics (ARCT) Announces $2.3 Million Additional Registered Direct Offering of Common Stock
August 2, 2019 2:03 PM EDTArcturus Therapeutics (Nasdaq: ARCT) a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has entered into a definitive agreement with an institutional investor for the purchase and sale in a registered direct offering of 200,000 shares of the Companys common stock, at a purchase price of $11.50 per share, for aggregate gross proceeds of $2.3 million. The offering is expected to close on or about August 5, 2019, subject to the satisfaction of customary... More
